Abstract
Recent technologic and therapeutic advances have improved the life of the patient with end-stage renal disease. High efficiency and high-flux hemodialyzer membranes have shortened the time required to dialyze, and recombinant erythropoietin has all but eliminated anemia as a major cause of morbidity, but the problem of renal osteodystrophy remains. The following discussion examines the spectrum of bone and joint disease in the patient with end-stage renal disease. The diagnostic and therapeutic strategies currently being tried in the management of these disorders are discussed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 192-205 |
| Number of pages | 14 |
| Journal | American Journal of the Medical Sciences |
| Volume | 306 |
| Issue number | 3 |
| DOIs | |
| State | Published - 1993 |
Keywords
- Aluminum-induced osteomalacia
- Calcitriol
- Deferoximine
- Hemodialysis-related amyloidosis
- Parathyroidectomy
- Renal osteodystrophy
ASJC Scopus subject areas
- Medicine(all)